Algae Dynamics Corp. (OTCQB: ADYNF), a Canadian company engaged in developing proprietary research as well as products derived from cannabis and hemp oils, has commenced a collaborative relationship with Dr. Laviolette, a neuroscientist at the University of Western Ontario, Canada, who is examining the treatment potential of cannabinoids in addressing disorders like addiction, schizophrenia, depression and post-traumatic stress disorder. Dr. Laviolette has been seeking ways to more effectively utilize chemicals found in marijuana to treat some of these illnesses, while Algae Dynamics has been taking a holistic approach by examining specific cannabinoids found in marijuana and combining that research with expertise in extracting various nutritional dietary products, like Omega-3 fatty acids. An article further discussing this topic reads: “Emerging research shows that Omega-3 fatty acids can have very strong interactions with the brain’s natural or biological endocannabinoid system and can also modulate the effects of cannabinoids on the brain. If there is a dietary deficiency of Omega-3 fatty acids, the brain’s natural cannabinoid system is not going to work with optimal efficiency,” Dr. Laviolette explained. “’By contrast, if you can supplement with Omega-3 fatty acids you see certain improvements in the brain’s cannabinoid system, so that immediately got us interested in how synergies between Omega-3 fatty acids and cannabinoids that are derived from marijuana might serve as potential, novel pharmaceutical and nutraceutical products for treating certain specific mental health disorders.’ The brain’s natural cannabinoid system is involved in a lot of different processes that relate to mental health, including mood regulation, one’s ability to learn and remember, and certain cognitive tasks.”
Read the full article
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Algae Dynamics Corp. (ADYNF) Collaborates with Prominent Neuroscientist to Research Cannabinoid Potential in Treating Mental Health Disorders
